SCHEMBL4295553

SCHEMBL4295553

CCCC[Sn](CCCC)(CCCC)c1nnn(Cc2ccccc2)c1-c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.46
DAPK3 O43293 2/20 0.46
ROCK2 O75116 2/20 0.46
PRKD3 O94806 2/20 0.46
MAP4K4 O95819 2/20 0.46
PRKACA P17612 2/20 0.46
CDK2 P24941 2/20 0.46
FLT3 P36888 2/20 0.46
CLK2 P49760 2/20 0.46
GSK3B P49841 2/20 0.46
CDK9 P50750 2/20 0.46
PRKX P51817 2/20 0.46
JAK3 P52333 2/20 0.46
CDK5 Q00535 2/20 0.46
MAP4K2 Q12851 2/20 0.46
CAMK2D Q13557 2/20 0.46
DYRK1A Q13627 2/20 0.46
PKN2 Q16513 2/20 0.46
MINK1 Q8N4C8 2/20 0.46
STK17A Q9UEE5 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3670826 0.92 CDC7 (0.41) CDC7DAPK3ROCK2PRKD3MAP4K4
SCHEMBL3669940 0.92 CYP19A1 (0.48) CDC7DAPK3ROCK2PRKD3MAP4K4
SCHEMBL3673183 0.87 CDC7 (0.48) CDC7DAPK3ROCK2PRKD3MAP4K4
SCHEMBL4638838 0.80 POLB (0.38) CYP19A1GRM2
SCHEMBL4292554 0.80 CDC7 (0.44) CDC7DAPK3PRKD3MAP4K4PRKACA
SCHEMBL4292592 0.79 GRM2 (0.41) CDC7DAPK3ROCK2PRKD3MAP4K4
SCHEMBL4284826 0.78 KMT2A (0.48) CDC7CYP19A1IDO1TDO2GRM2
SCHEMBL4291497 0.77 GRM2 (0.39) CDC7CYP19A1IDO1GRM2SLC9A1
SCHEMBL4295575 0.75 CDC7 (0.49) CDC7
SCHEMBL3667322 0.74 ROCK2 (0.43) CDC7DAPK3ROCK2MAP4K4PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885DAPK3 226/4885ROCK2 48/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885DAPK3 226/4885ROCK2 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.